UAE’s Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) and Quris-AI, an Israel-based artificial intelligence (AI) innovator, have signed an agreement during Abu Dhabi Sustainability Week (ADSW) to develop a world-class Bio-AI center in Abu Dhabi.
The state-of-the-art facility will support the development of personalized medications, tailored specifically to the diverse populations of the MENA region.
The collaboration will establish a center of excellence in Bio-AI in Abu Dhabi, which will accelerate the development of safer, and more highly personalized medications. MBZUAI provides expertise in the development of predictive AI models, while incentivizing sought-after AI graduates to stay in the UAE as they begin their careers.
Quris-AI developed the world’s first Bio-AI clinical prediction platform, which makes drug development faster and more efficient, and promises to save hundreds of millions of dollars in research and development costs. With this collaboration, Quris, which has operations in Boston and Tel-Aviv, is now establishing its subsidiary, Quris-UAE in Abu-Dhabi.
Isaac Bentwich Founder & CEO Quris AI
“We are delighted to be collaborating with MBZUAI in Abu Dhabi, given its strong commitment to advancing AI and significant opportunities for synergy. We salute the vision of H.H. Sheikh Mohamed bin Zayed Al Nahyan, championing the UAE to become a center of excellence in AI as a strong pillar of the economy, and we are honored to contribute to realizing this vision.”
Currently, around 90 percent of clinical trials for new medications end in failure, but Quris’ proprietary ‘patient-on-a-chip’ technology promises to reduce failure by predicting which drugs are most likely to work in humans. The Quris system rapidly performs test interactions using predictive AI technologies that simulate genetically diverse patients, eliminating the need for animal testing and avoiding the risk and cost associated with failed clinical trials.
